Overview

A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)

Status:
Completed

Trial end date:
2005-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the long term safety of patients with refractory solid tumors who have experienced clinical benefit after at least 6 cycles of treatment in BMS Protocol CA124-001 or CA124-002.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Camptothecin
Carboplatin
Irinotecan